Evelyne W.
- Country
- Belgium
- Department
- Hematology
Research Overview
- A phase I/II, multicenter study evaluating the feasibility, safety, and efficacy of point-of-care manufactured GLPG5101 (19CP02) in subjects with relapsed/refractory B-cell non-Hodgkin lymphoma
- Phase III Multicenter Trial of Allogeneic CD4+ and CD8+ T Lymphocytes for Chemo-Refractory CMV, EBV, and AdV Infections Post-Allogeneic Stem Cell Transplantation
- Evaluation of Cumulative Fludarabine Exposure in Hematological Malignancy Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation
Data & Insights
Has run more than one trial at 69 of 139 partner sites.
Specializations
Transplant Complications
This investigator specializes in treating various complications following hematopoietic stem cell transplantation and organ transplantation. Their research encompasses both acute and chronic manifestations of graft-versus-host disease, with particular attention to gastrointestinal involvement.
- Acute and chronic GVHD management
- Post-transplant viral infections
- Transplant-associated thrombotic microangiopathy
Hematologic Malignancies
The investigator focuses on treating various forms of blood cancers, particularly addressing resistant and relapsed cases. Their work includes innovative approaches to non-Hodgkin lymphoma and chronic lymphocytic leukemia.
- B-cell non-Hodgkin lymphoma
- Multiple myeloma
- Post-transplant lymphoproliferative disease
Advanced Therapeutics
The investigator explores cutting-edge therapeutic approaches, including CAR T-cell therapy and novel pharmaceutical interventions. Their work involves multispecific T-cell transfer and innovative drug combinations for transplant-related conditions.
- Cell-based immunotherapies
- Novel drug combinations
- Long-term therapeutic monitoring
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.